Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 16, 2022

SELL
$4.22 - $5.85 $56,691 - $78,588
-13,434 Closed
0 $0
Q1 2022

May 17, 2022

SELL
$5.43 - $6.81 $40,583 - $50,897
-7,474 Reduced 35.75%
13,434 $74,000
Q4 2021

Feb 15, 2022

SELL
$5.21 - $6.82 $26,425 - $34,591
-5,072 Reduced 19.52%
20,908 $138,000
Q3 2021

Nov 16, 2021

SELL
$5.25 - $5.87 $59,157 - $66,143
-11,268 Reduced 30.25%
25,980 $138,000
Q2 2021

Aug 16, 2021

SELL
$5.67 - $6.33 $75,524 - $84,315
-13,320 Reduced 26.34%
37,248 $217,000
Q1 2021

May 18, 2021

BUY
$6.02 - $8.06 $152,071 - $203,603
25,261 Added 99.82%
50,568 $313,000
Q4 2020

Feb 17, 2021

SELL
$6.3 - $8.46 $42,732 - $57,384
-6,783 Reduced 21.14%
25,307 $164,000
Q3 2020

Nov 17, 2020

BUY
$8.02 - $11.73 $98,389 - $143,903
12,268 Added 61.89%
32,090 $268,000
Q2 2020

Aug 17, 2020

SELL
$5.37 - $9.45 $207,045 - $364,354
-38,556 Reduced 66.05%
19,822 $154,000
Q1 2020

May 15, 2020

BUY
$4.56 - $7.13 $2,307 - $3,607
506 Added 0.87%
58,378 $340,000
Q4 2019

Feb 14, 2020

BUY
$4.97 - $7.7 $99,355 - $153,930
19,991 Added 52.77%
57,872 $395,000
Q3 2019

Nov 14, 2019

SELL
$5.11 - $5.99 $108,735 - $127,461
-21,279 Reduced 35.97%
37,881 $194,000
Q2 2019

Aug 15, 2019

BUY
$5.39 - $6.26 $261,716 - $303,960
48,556 Added 457.9%
59,160 $327,000
Q1 2019

May 16, 2019

BUY
$5.12 - $6.18 $54,292 - $65,532
10,604 New
10,604 $61,000
Q4 2018

Feb 15, 2019

SELL
$4.68 - $6.25 $87,005 - $116,193
-18,591 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$5.15 - $6.3 $48,590 - $59,440
-9,435 Reduced 33.67%
18,591 $115,000
Q2 2018

Aug 15, 2018

BUY
$4.4 - $5.3 $123,314 - $148,537
28,026 New
28,026 $146,000
Q4 2017

Feb 15, 2018

SELL
$4.35 - $5.15 $101,281 - $119,907
-23,283 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$4.25 - $4.8 $98,952 - $111,758
23,283
23,283 $112,000

Others Institutions Holding KMDA

About KAMADA LTD


  • Ticker KMDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 44,800,500
  • Market Cap $263M
  • Description
  • Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytop...
More about KMDA
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.